Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma
Figure 1
Representative images showing the presence of SALL4 protein in liver cancer and noncancerous tissue sections. (a) The positive expression of SALL4 in hepatocellular carcinoma tissues (the scoring is 2+); (b) the negative expression of SALL4 in liver tissues with chronic hepatitis B virus; (c) the negative expression of SALL4 in liver samples with liver cirrhosis; and (d) the negative expression of SALL4 in liver samples of health controls. (400x magnification).
